These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 16203782)

  • 21. First study of the safety, tolerability, and pharmacokinetics of CP-724,714 in patients with advanced malignant solid HER2-expressing tumors.
    Munster PN; Britten CD; Mita M; Gelmon K; Minton SE; Moulder S; Slamon DJ; Guo F; Letrent SP; Denis L; Tolcher AW
    Clin Cancer Res; 2007 Feb; 13(4):1238-45. PubMed ID: 17317835
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase I safety, pharmacokinetics, and inhibition of SRC activity study of saracatinib in patients with solid tumors.
    Baselga J; Cervantes A; Martinelli E; Chirivella I; Hoekman K; Hurwitz HI; Jodrell DI; Hamberg P; Casado E; Elvin P; Swaisland A; Iacona R; Tabernero J
    Clin Cancer Res; 2010 Oct; 16(19):4876-83. PubMed ID: 20805299
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A study to determine the effects of food and multiple dosing on the pharmacokinetics of vorinostat given orally to patients with advanced cancer.
    Rubin EH; Agrawal NG; Friedman EJ; Scott P; Mazina KE; Sun L; Du L; Ricker JL; Frankel SR; Gottesdiener KM; Wagner JA; Iwamoto M
    Clin Cancer Res; 2006 Dec; 12(23):7039-45. PubMed ID: 17145826
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A phase I and pharmacokinetic study of Col-3 (Metastat), an oral tetracycline derivative with potent matrix metalloproteinase and antitumor properties.
    Syed S; Takimoto C; Hidalgo M; Rizzo J; Kuhn JG; Hammond LA; Schwartz G; Tolcher A; Patnaik A; Eckhardt SG; Rowinsky EK
    Clin Cancer Res; 2004 Oct; 10(19):6512-21. PubMed ID: 15475438
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase I dose-escalating study of SU11654, a small molecule receptor tyrosine kinase inhibitor, in dogs with spontaneous malignancies.
    London CA; Hannah AL; Zadovoskaya R; Chien MB; Kollias-Baker C; Rosenberg M; Downing S; Post G; Boucher J; Shenoy N; Mendel DB; McMahon G; Cherrington JM
    Clin Cancer Res; 2003 Jul; 9(7):2755-68. PubMed ID: 12855656
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced cancer.
    Carducci MA; Musib L; Kies MS; Pili R; Truong M; Brahmer JR; Cole P; Sullivan R; Riddle J; Schmidt J; Enas N; Sinha V; Thornton DE; Herbst RS
    J Clin Oncol; 2006 Sep; 24(25):4092-9. PubMed ID: 16943527
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase I clinical and pharmacological evaluation of the multi-tyrosine kinase inhibitor SU006668 by chronic oral dosing.
    Sessa C; Viganò L; Grasselli G; Trigo J; Marimon I; Lladò A; Locatelli A; Ielmini N; Marsoni S; Gianni L
    Eur J Cancer; 2006 Jan; 42(2):171-8. PubMed ID: 16406576
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase I and pharmacokinetic study of the novel oral cell-cycle inhibitor Ro 31-7453 in patients with advanced solid tumors.
    Dupont J; Bienvenu B; Aghajanian C; Pezzulli S; Sabbatini P; Vongphrachanh P; Chang C; Perkell C; Ng K; Passe S; Breimer L; Zhi J; DeMario M; Spriggs D; Soignet SL
    J Clin Oncol; 2004 Aug; 22(16):3366-74. PubMed ID: 15310782
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A phase I clinical and pharmacokinetic study of Ro 31-7453 given as a 7- or 14-day oral twice daily schedule every 4 weeks in patients with solid tumors.
    Salazar R; Bissett D; Twelves C; Breimer L; DeMario M; Campbell S; Zhi J; Ritland S; Cassidy J
    Clin Cancer Res; 2004 Jul; 10(13):4374-82. PubMed ID: 15240525
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase I study to determine the safety and pharmacokinetics of oral administration of TAS-102 in patients with solid tumors.
    Hong DS; Abbruzzese JL; Bogaard K; Lassere Y; Fukushima M; Mita A; Kuwata K; Hoff PM
    Cancer; 2006 Sep; 107(6):1383-90. PubMed ID: 16902987
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Phase I and pharmacological study with imidazolium-trans-DMSO-imidazole-tetrachlororuthenate, a novel ruthenium anticancer agent.
    Rademaker-Lakhai JM; van den Bongard D; Pluim D; Beijnen JH; Schellens JH
    Clin Cancer Res; 2004 Jun; 10(11):3717-27. PubMed ID: 15173078
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase I and pharmacological study of the oral matrix metalloproteinase inhibitor, MMI270 (CGS27023A), in patients with advanced solid cancer.
    Levitt NC; Eskens FA; O'Byrne KJ; Propper DJ; Denis LJ; Owen SJ; Choi L; Foekens JA; Wilner S; Wood JM; Nakajima M; Talbot DC; Steward WP; Harris AL; Verweij J
    Clin Cancer Res; 2001 Jul; 7(7):1912-22. PubMed ID: 11448904
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A phase I, first in man study of OSI-7836 in patients with advanced refractory solid tumors: IND.147, a study of the Investigational New Drug Program of the National Cancer Institute of Canada Clinical Trials Group.
    Goss G; Siu LL; Gauthier I; Chen EX; Oza AM; Goel R; Maroun J; Powers J; Walsh W; Maclean M; Drolet DW; Rusk J; Seymour LK;
    Cancer Chemother Pharmacol; 2006 Nov; 58(5):703-10. PubMed ID: 16528532
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dose-ranging study of the safety and pharmacokinetics of atrasentan in patients with refractory malignancies.
    Ryan CW; Vogelzang NJ; Vokes EE; Kindler HL; Undevia SD; Humerickhouse R; André AK; Wang Q; Carr RA; Ratain MJ
    Clin Cancer Res; 2004 Jul; 10(13):4406-11. PubMed ID: 15240529
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors.
    Strumberg D; Richly H; Hilger RA; Schleucher N; Korfee S; Tewes M; Faghih M; Brendel E; Voliotis D; Haase CG; Schwartz B; Awada A; Voigtmann R; Scheulen ME; Seeber S
    J Clin Oncol; 2005 Feb; 23(5):965-72. PubMed ID: 15613696
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A phase I study of foretinib, a multi-targeted inhibitor of c-Met and vascular endothelial growth factor receptor 2.
    Eder JP; Shapiro GI; Appleman LJ; Zhu AX; Miles D; Keer H; Cancilla B; Chu F; Hitchcock-Bryan S; Sherman L; McCallum S; Heath EI; Boerner SA; LoRusso PM
    Clin Cancer Res; 2010 Jul; 16(13):3507-16. PubMed ID: 20472683
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A phase II, pharmacokinetic, and biologic study of semaxanib and thalidomide in patients with metastatic melanoma.
    Mita MM; Rowinsky EK; Forero L; Eckhart SG; Izbicka E; Weiss GR; Beeram M; Mita AC; de Bono JS; Tolcher AW; Hammond LA; Simmons P; Berg K; Takimoto C; Patnaik A
    Cancer Chemother Pharmacol; 2007 Feb; 59(2):165-74. PubMed ID: 16736151
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases.
    Medina PJ; Goodin S
    Clin Ther; 2008 Aug; 30(8):1426-47. PubMed ID: 18803986
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Satraplatin, an oral platinum, administered on a five-day every-five-week schedule: a pharmacokinetic and food effect study.
    Ricart AD; Sarantopoulos J; Calvo E; Chu QS; Greene D; Nathan FE; Petrone ME; Tolcher AW; Papadopoulos KP
    Clin Cancer Res; 2009 Jun; 15(11):3866-71. PubMed ID: 19458055
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase 1 study of weekly polyethylene glycol-camptothecin in patients with advanced solid tumors and lymphomas.
    Posey JA; Saif MW; Carlisle R; Goetz A; Rizzo J; Stevenson S; Rudoltz MS; Kwiatek J; Simmons P; Rowinsky EK; Takimoto CH; Tolcher AW
    Clin Cancer Res; 2005 Nov; 11(21):7866-71. PubMed ID: 16278410
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.